CINECA IRIS Institutional Research Information System

SALVATORE, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.726
AS - Asia 764
EU - Europa 613
SA - Sud America 111
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.269
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.686
SG - Singapore 283
CN - Cina 200
IT - Italia 148
DE - Germania 122
HK - Hong Kong 97
BR - Brasile 83
VN - Vietnam 78
SE - Svezia 73
FR - Francia 52
BG - Bulgaria 46
GB - Regno Unito 41
CA - Canada 34
FI - Finlandia 31
RU - Federazione Russa 29
AT - Austria 24
IN - India 20
SN - Senegal 18
BD - Bangladesh 14
CI - Costa d'Avorio 13
TR - Turchia 13
NG - Nigeria 10
NL - Olanda 9
IQ - Iraq 8
AR - Argentina 7
VE - Venezuela 7
EC - Ecuador 6
JP - Giappone 6
MX - Messico 6
SA - Arabia Saudita 6
ID - Indonesia 5
PK - Pakistan 5
UA - Ucraina 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
EG - Egitto 4
IL - Israele 4
PH - Filippine 4
AL - Albania 3
CO - Colombia 3
CZ - Repubblica Ceca 3
IE - Irlanda 3
MY - Malesia 3
PL - Polonia 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
ES - Italia 2
LT - Lituania 2
NO - Norvegia 2
PT - Portogallo 2
PY - Paraguay 2
UY - Uruguay 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BJ - Benin 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
KR - Corea 1
LK - Sri Lanka 1
LV - Lettonia 1
MN - Mongolia 1
NP - Nepal 1
PE - Perù 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.269
Salva come PNG Salva come JPEG
Città #
Woodbridge 231
Ashburn 210
Singapore 171
Fairfield 149
Santa Clara 114
Hong Kong 94
Boardman 83
Chandler 80
Seattle 73
Houston 71
San Jose 69
Cambridge 59
Ann Arbor 51
Shanghai 50
Wilmington 48
Sofia 46
Beijing 43
New York 38
Dallas 33
Pisa 27
Princeton 23
Vienna 20
Hanoi 19
Ottawa 19
Dakar 18
Helsinki 18
Lawrence 18
Des Moines 17
Lauterbourg 16
Los Angeles 16
Medford 16
Bremen 14
Düsseldorf 14
London 14
Abidjan 13
Dong Ket 13
Florence 13
Ho Chi Minh City 13
Dearborn 12
Frankfurt am Main 12
Marseille 12
Munich 12
Buffalo 10
Istanbul 10
Lagos 10
Rome 10
Orem 9
Phoenix 9
Redwood City 9
Milan 8
Nuremberg 8
São Paulo 8
Nanjing 7
Toronto 7
Turin 7
Guangzhou 6
Lancaster 6
Seacroft 6
Serra 6
Changsha 5
Kunming 5
Positano 5
Redondo Beach 5
San Diego 5
San Francisco 5
Tokyo 5
Baghdad 4
Boulder 4
Brooklyn 4
Chicago 4
Curitiba 4
Lusciano 4
Montreal 4
Polverigi 4
Rio de Janeiro 4
Shenyang 4
Tianjin 4
Brasília 3
Bắc Ninh 3
Da Nang 3
Dhaka 3
Dublin 3
Guayaquil 3
Hebei 3
Jeddah 3
Johannesburg 3
Leawood 3
Mumbai 3
Nürnberg 3
Paris 3
Stockholm 3
Tashkent 3
Turku 3
Vũng Tàu 3
Warsaw 3
Amsterdam 2
Atlanta 2
Baku 2
Belo Horizonte 2
Boston 2
Totale 2.361
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 269
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 215
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 187
TAS-102 for the treatment of metastatic colorectal cancer 179
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 175
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 166
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 164
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 162
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 156
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 156
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 151
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 150
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 139
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 136
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 122
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 105
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 100
null 98
null 85
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 85
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 82
First-line chemotherapy for mCRC-a review and evidence-based algorithm 82
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 67
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers 57
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials 41
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study 3
PTEN expression and KRAS mutations in the prediction of benefit from cetuximab plus irinotecan in metastatic colorectal cancer 3
Totale 3.335
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 11 19 23
2021/2022214 3 9 2 3 34 36 4 5 19 13 9 77
2022/2023302 24 48 20 34 31 35 2 14 72 2 18 2
2023/2024160 13 11 24 6 20 27 14 13 4 2 7 19
2024/2025672 5 21 39 26 90 75 38 29 55 99 65 130
2025/2026872 61 78 47 49 137 129 159 53 71 88 0 0
Totale 3.335